CANASA vs OTULFI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. CANASA and OTULFI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	CANASA	OTULFI
Rating	72/100	68/100
Pharmacy pays	~$26.72 /30	—
Type	RX	RX
Active ingredient	MESALAMINE	USTEKINUMAB-AAUZ
Manufacturer	Abbvie	Fresenius Kabi USA
Dosage forms	Suppository	Injectable, Solution
Drug class	Aminosalicylate	—
Boxed warning	None	None
Half-life	about 7 to 9 hours (apparent terminal half-life)	—
Treats	Ulcerative Colitis, Proctitis, Sigmoid Diseases	Ulcerative Colitis, Crohn Disease, Psoriasis

canasa otulfi

Rating

72/100

68/100

Pharmacy pays

~$26.72 /30

—

Type

Active ingredient

MESALAMINE

USTEKINUMAB-AAUZ

Manufacturer

Abbvie

Fresenius Kabi USA

Dosage forms

Suppository

Injectable, Solution

Drug class

Aminosalicylate

—

Boxed warning

None

Half-life

about 7 to 9 hours (apparent terminal half-life)

—

Treats

Ulcerative Colitis, Proctitis, Sigmoid Diseases

Ulcerative Colitis, Crohn Disease, Psoriasis

Frequently asked questions

Which is better-rated, Canasa or Otulfi?

By our independent rating, Canasa scores higher — 3.6 vs 3.4 out of 5 for Otulfi. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Canasa and Otulfi?

Canasa contains Mesalamine, while Otulfi contains Ustekinumab-Aauz — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.